CORP
COlchicine for Recurrent Pericarditis
Paziente / Popolazione Intervento / Esposizione Confronto Esito
In 120 patients with a first recurrence of pericarditis, colchicine for 6 months added to conventional anti-inflammatory therapy halved further recurrence at 18 months compared with placebo.
N
120
Disegno
Double-blind, placebo-controlled RCT
Esito
Recurrence rate at 18 months
Rilevanza
2
Risultato24 % vs 55 % (absolute risk reduction 0.31, 95 % CI 0.13–0.46; relative risk reduction 0.56, 95 % CI 0.27–0.73; NNT 3). Side-effect and withdrawal rates similar.
Imazio M, Brucato A, Cemin R, et al. Ann Intern Med. 2011;155(7):409-414. 10.7326/0003-4819-155-7-201110040-00359
Discussione e critica
Small, single-country and restricted to a first recurrence of non-bacterial, non-neoplastic aetiology. It was the first properly blinded randomised demonstration that colchicine prevents relapse and, with ICAP and CORP-2, underpins the class-I recommendation.